CPHI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Home Market News Merck's Idenix Pharmaceuticals awarded $2.54 billion for infringement of a hepatitis C drug patent
News
16 Dec 2016

Merck's Idenix Pharmaceuticals awarded $2.54 billion for infringement of a hepatitis C drug patent

In its decision, the jury also concluded that Gilead “willfully” infringed upon the patent.

Merck (MSD) has announced that a jury in the US District Court for the District of Delaware ordered Gilead Sciences to pay $2.54 billion in damages for infringing upon an Idenix Pharmaceuticals patent for methods used to develop sofosbuvir-based medicines for the treatment of patients with hepatitis C virus (HCV) infection, including Sovaldi and Harvoni.

The jury’s verdict upholds patent protections that are essential to the development of new medical treatments. Given that it guarantees a period of return on investment, patent protection provides the research-based pharmaceutical and biotechnology industries with an incentive to invest in research and development.

The patent at issue in this case facilitated significant advances in the treatment of patients with HCV infection and was appropriately granted. Achieving these advancements required many years of research and significant investment by Merck's subsidiary and its partners.

The jury awarded the damages as compensation for infringement through August 2016. In its decision, the jury also concluded that Gilead “willfully” infringed upon the patent. As a result, Judge Leonard P. Stark, may, at his discretion, increase the damages award up to a multiple of three times.

Related tags
Market Policy & Regulation

Related News